



the **Hydroponics** company

www.thcl.com.au

ASX RELEASE (7th February 2018)

Clinic Rollout Update

KEY POINTS

- **Commencement of National Access Cannabis (NAC) clinic development**
- **Systems Implementation Manager, from NAC Canada, to support development of the clinic model in Australia**

The Hydroponics Company Limited (ASX:THC) (“THC”) advises it has recently completed a visit to several of the clinics owned and managed by National Access Cannabis in Canada. The objective of the visit was to commence the transfer of information and localisation of the clinic model to the Australian market.

NAC is a leading provider of clinic services to medicinal cannabis patients in Canada.

The model that NAC follows was identified as being a strong fit with the developing Australian market in that it provides a highly differentiated service offering:

- Patient education on Licensed Producers, strains, methods of consumption and dosing guidelines
- Trusted partner to health care professionals, providing education and expert advice as they commence prescribing medicinal cannabis
- Data collection to facilitate both policy and clinical practice decision making

THC confirms its business partner NAC-Canada will make their Systems Implementation Manager available onsite in Sydney on secondment to assist with the development and implementation of a clinic roll out plan.



The Hydroponics Company Limited
(ASX: THC) ACN: 614 508 039

Suite 305, Level 3,
35 Lime Street
Sydney NSW 2000

For personal use only

The focus of this Sydney based role will be to transfer intellectual property from NAC Canada in the form of operational support as THC accelerates plans for the first clinic model.

Upon commencement of the NAC model, THC will:

- Provide a patient centric, tailored solution to facilitate prescribing of medicinal cannabis
- Provide regular support, ongoing education and care for eligible patients
- Commence collection of clinical data to contribute to the body of evidence and advance our understanding of the benefits of medicinal cannabis in a controlled and managed process

David Radford of THC states:

“the medicinal cannabis clinics in Canada have been instrumental in developing the demand side of the business. The Australian market has many similarities to the Canadian market at a clinical level, with an identified need for excellence in training and patient support as key success factors to aid market development.

The roll out of the NAC clinic model is an exciting business opportunity that positions THC as a best practice leader in the provision of safe and responsible access to medicinal cannabis in Australia.”

THC is targeting the first clinic to be opened in Q2-18.

For further information, please contact:



David Radford
Chief Executive Officer
The Hydroponics Company Limited

Suite 305, Level 3, 35 Lime Street
Sydney NSW 2000

P: +61 2 8296 0000



Michael Lovesey
Director Corporate Media Relations
MMR Corporate Services Pty Ltd

Level 2, 131 Macquarie Street
Sydney, NSW 2000 Australia

P: +61 2 9251 7177

M: +61 449 607 636

E: michaell@mmlrcorporate.com

About The Hydroponics Company

The Hydroponics Company (ASX: THC) is at the forefront of developing a leading, diversified worldwide cannabis business, focused on three core business units: Development and delivery of medicinal cannabis, manufacturing and distribution of hydroponics equipment, materials and nutrients, and large scale hydroponic greenhouse design and construction. With +17 years of Cannabis sativa breeding, variety selection and growth management, THC is actively developing plant breeding technology to target multiple markets for high purity cannabidiol (CBD), a new class of medicinal product that can be used to target dementia, epilepsy and other neurological disorders.

For personal use only